<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37101169</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1423-0127</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>26</Day></PubDate></JournalIssue><Title>Journal of biomedical science</Title><ISOAbbreviation>J Biomed Sci</ISOAbbreviation></Journal><ArticleTitle>Degradation of neurodegenerative disease-associated TDP-43 aggregates and oligomers via a proteolysis-targeting chimera.</ArticleTitle><Pagination><StartPage>27</StartPage><MedlinePgn>27</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">27</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12929-023-00921-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Amyotrophic lateral sclerosis (ALS) associated with TAR DNA-binding protein 43 (TDP-43) aggregation has been considered as a lethal and progressive motor neuron disease. Recent studies have shown that both C-terminal TDP-43 (C-TDP-43) aggregates and oligomers were neurotoxic and pathologic agents in ALS and frontotemporal lobar degeneration (FTLD). However, misfolding protein has long been considered as an undruggable target by applying conventional inhibitors, agonists, or antagonists. To provide this unmet medical need, we aim to degrade these misfolding proteins by designing a series of proteolysis targeting chimeras (PROTACs) against C-TDP-43.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">By applying filter trap assay, western blotting, and microscopy imaging, the degradation efficiency of C-TDP-43 aggregates was studied in Neuro-2a cells overexpressing eGFP-C-TDP-43 or mCherry-C-TDP-43. The cell viability was characterized by alarmarBlue assay. The beneficial and disaggregating effects of TDP-43 PROTAC were examined with the YFP-C-TDP-43 transgenic C. elegans by motility assay and confocal microscopy. The impact of TDP-43 PROTAC on C-TDP-43 oligomeric intermediates was monitored by fluorescence lifetime imaging microscopy and size exclusion chromatography in the Neuro-2a cells co-expressing eGFP-C-TDP-43 and mCherry-C-TDP-43.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Four PROTACs with different linker lengths were synthesized and characterized. Among these chimeras, PROTAC 2 decreased C-TDP-43 aggregates and relieved C-TDP-43-induced cytotoxicity in Neuro-2a cells without affecting endogenous TDP-43. We showed that PROTAC 2 bound to C-TDP-43 aggregates and E3 ligase to initiate ubiquitination and proteolytic degradation. By applying advanced microscopy, it was further shown that PROTAC 2 decreased the compactness and population of C-TDP-43 oligomers. In addition to cellular model, PROTAC 2 also improved the motility of transgenic C. elegans by reducing the C-TDP-43 aggregates in the nervous system.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our study demonstrated the dual-targeting capacity of the newly-designed PROTAC 2 against both C-TDP-43 aggregates and oligomers to reduce their neurotoxicity, which shed light on the potential drug development for ALS as well as other neurodegenerative diseases.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Tseng</LastName><ForeName>Yu-Ling</ForeName><Initials>YL</Initials><AffiliationInfo><Affiliation>Department of Chemistry, National Taiwan University, Taipei, 106, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Lu</LastName><ForeName>Po-Chao</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Institute of Chemistry, Academia Sinica, Taipei, 115, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chemical Biology and Molecular Biophysics, Taiwan International Graduate Program, Academia Sinica, Taipei, 115, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department and Graduate Institute of Pharmacology, National Taiwan University, Taipei, 100, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Chi-Chang</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Institute of Chemistry, Academia Sinica, Taipei, 115, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Ruei-Yu</ForeName><Initials>RY</Initials><AffiliationInfo><Affiliation>Institute of Chemistry, Academia Sinica, Taipei, 115, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yung-An</ForeName><Initials>YA</Initials><AffiliationInfo><Affiliation>Institute of Chemistry, Academia Sinica, Taipei, 115, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tseng</LastName><ForeName>Yin-Chen</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>The Genomics Research Center, Academia Sinica, Taipei, 115, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Ting-Jen Rachel</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>The Genomics Research Center, Academia Sinica, Taipei, 115, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Joseph Jen-Tse</ForeName><Initials>JJ</Initials><Identifier Source="ORCID">0000-0003-4847-7126</Identifier><AffiliationInfo><Affiliation>Institute of Chemistry, Academia Sinica, Taipei, 115, Taiwan. jthuang@gate.sinica.edu.tw.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sustainable Chemical Science and Technology, Taiwan International Graduate Program, Academia Sinica, Taipei, 115, Taiwan. jthuang@gate.sinica.edu.tw.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Applied Chemistry, National Chiayi University, Chiayi City, 600, Taiwan. jthuang@gate.sinica.edu.tw.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Program of Academia Sinica, Academia Sinica, Taipei, 115, Taiwan. jthuang@gate.sinica.edu.tw.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Jim-Min</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-6070-3408</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, National Taiwan University, Taipei, 106, Taiwan. jmfang@ntu.edu.tw.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Genomics Research Center, Academia Sinica, Taipei, 115, Taiwan. jmfang@ntu.edu.tw.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AS-CDA-109-M09</GrantID><Agency>Academia Sinica</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Biomed Sci</MedlineTA><NlmUniqueID>9421567</NlmUniqueID><ISSNLinking>1021-7770</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059748" MajorTopicYN="N">Proteolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017173" MajorTopicYN="N">Caenorhabditis elegans</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aggregate and oligomer</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Neurodegenerative diseases</Keyword><Keyword MajorTopicYN="N">PROTACs</Keyword><Keyword MajorTopicYN="N">Protein degradation</Keyword><Keyword MajorTopicYN="N">TDP-43 cytotoxicity</Keyword><Keyword MajorTopicYN="N">Transgenic C. elegans</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>27</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>26</Day><Hour>23</Hour><Minute>37</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37101169</ArticleId><ArticleId IdType="pmc">PMC10131537</ArticleId><ArticleId IdType="doi">10.1186/s12929-023-00921-7</ArticleId><ArticleId IdType="pii">10.1186/s12929-023-00921-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sweeney P, et al. Protein misfolding in neurodegenerative diseases: implications and strategies. Transl Neurodegener. 2017;6:6. doi: 10.1186/s40035-017-0077-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-017-0077-5</ArticleId><ArticleId IdType="pmc">PMC5348787</ArticleId><ArticleId IdType="pubmed">28293421</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou Y, et al. Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol. 2019;15:565&#x2013;581. doi: 10.1038/s41582-019-0244-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-019-0244-7</ArticleId><ArticleId IdType="pubmed">31501588</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Hardy J, Fischbeck KH. Toxic proteins in neurodegenerative disease. Science. 2002;296:1991&#x2013;1995. doi: 10.1126/science.1067122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1067122</ArticleId><ArticleId IdType="pubmed">12065827</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamptey RNL, et al. A review of the common neurodegenerative disorders: current therapeutic approaches and the potential role of nanotherapeutics. Int J Mol Sci. 2022;23:1851. doi: 10.3390/ijms23031851.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23031851</ArticleId><ArticleId IdType="pmc">PMC8837071</ArticleId><ArticleId IdType="pubmed">35163773</ArticleId></ArticleIdList></Reference><Reference><Citation>Akhtar A, et al. Neurodegenerative diseases and effective drug delivery: a review of challenges and novel therapeutics. J Control Release. 2021;330:1152&#x2013;1167. doi: 10.1016/j.jconrel.2020.11.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2020.11.021</ArticleId><ArticleId IdType="pubmed">33197487</ArticleId></ArticleIdList></Reference><Reference><Citation>Onos KD, Sukoff Rizzo SJ, Howell GR, Sasner M. Toward more predictive genetic mouse models of Alzheimer's disease. Brain Res Bull. 2016;122:1&#x2013;11. doi: 10.1016/j.brainresbull.2015.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2015.12.003</ArticleId><ArticleId IdType="pmc">PMC4843786</ArticleId><ArticleId IdType="pubmed">26708939</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai AC, et al. Modular PROTAC design for the degradation of oncogenic BCR-ABL. Angew Chem Int Ed Engl. 2016;55:807&#x2013;810. doi: 10.1002/anie.201507634.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.201507634</ArticleId><ArticleId IdType="pmc">PMC4733637</ArticleId><ArticleId IdType="pubmed">26593377</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Dixit VM. Drugging the undruggables: exploring the ubiquitin system for drug development. Cell Res. 2016;26:484&#x2013;498. doi: 10.1038/cr.2016.31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cr.2016.31</ArticleId><ArticleId IdType="pmc">PMC4822129</ArticleId><ArticleId IdType="pubmed">27002218</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomoshige S, Nomura S, Ohgane K, Hashimoto Y, Ishikawa M. Discovery of small molecules that induce the degradation of huntingtin. Angew Chem Int Ed. 2017;56:11530&#x2013;11533. doi: 10.1002/anie.201706529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.201706529</ArticleId><ArticleId IdType="pubmed">28703441</ArticleId></ArticleIdList></Reference><Reference><Citation>Churcher I. Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones? J Med Chem. 2018;61:444&#x2013;452. doi: 10.1021/acs.jmedchem.7b01272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.7b01272</ArticleId><ArticleId IdType="pubmed">29144739</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoh Y. Chemical protein degradation approach and its application to epigenetic targets. Chem Rec. 2018;18:1681&#x2013;1700. doi: 10.1002/tcr.201800032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/tcr.201800032</ArticleId><ArticleId IdType="pubmed">29893461</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou Y, Ma D, Wang Y. The PROTAC technology in drug development. Cell Biochem Funct. 2019;37:21&#x2013;30. doi: 10.1002/cbf.3369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbf.3369</ArticleId><ArticleId IdType="pmc">PMC6590639</ArticleId><ArticleId IdType="pubmed">30604499</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, et al. PROTACs: great opportunities for academia and industry. Signal Transduct Target Ther. 2019;4:64. doi: 10.1038/s41392-019-0101-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-019-0101-6</ArticleId><ArticleId IdType="pmc">PMC6927964</ArticleId><ArticleId IdType="pubmed">31885879</ArticleId></ArticleIdList></Reference><Reference><Citation>Groppe JC. Induced degradation of protein kinases by bifunctional small molecules: a next-generation strategy. Expert Opin Drug Discov. 2019;14:1237&#x2013;1253. doi: 10.1080/17460441.2019.1660641.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17460441.2019.1660641</ArticleId><ArticleId IdType="pubmed">31513432</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishikawa M, Tomoshige S, Demizu Y, Naito M. Selective degradation of target proteins by chimeric small-molecular drugs PROTACs and SNIPERs. Pharmaceuticals (Basel) 2020;13:74. doi: 10.3390/ph13040074.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph13040074</ArticleId><ArticleId IdType="pmc">PMC7243126</ArticleId><ArticleId IdType="pubmed">32326273</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomaselli D, Mautone N, Mai A, Rotili D. Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs) Eur J Med Chem. 2020;207:112750. doi: 10.1016/j.ejmech.2020.112750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2020.112750</ArticleId><ArticleId IdType="pubmed">32871345</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomoshige S, Ishikawa M. PROTACs and other chemical protein degradation technologies for the treatment of neurodegenerative disorders. Angew Chem Int Ed Engl. 2021;60:3346&#x2013;3354. doi: 10.1002/anie.202004746.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.202004746</ArticleId><ArticleId IdType="pubmed">32410219</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondeson DP, et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat Chem Biol. 2015;11:611&#x2013;617. doi: 10.1038/nchembio.1858.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.1858</ArticleId><ArticleId IdType="pmc">PMC4629852</ArticleId><ArticleId IdType="pubmed">26075522</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshaies RJ, Joazeiro CA. RING domain E3 ubiquitin ligases. Annu Rev Biochem. 2009;78:399&#x2013;434. doi: 10.1146/annurev.biochem.78.101807.093809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.biochem.78.101807.093809</ArticleId><ArticleId IdType="pubmed">19489725</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Jiang X, Feng F, Liu W, Sun H. Degradation of proteins by PROTACs and other strategies. Acta Pharm Sin B. 2020;10:207&#x2013;238. doi: 10.1016/j.apsb.2019.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2019.08.001</ArticleId><ArticleId IdType="pmc">PMC7016280</ArticleId><ArticleId IdType="pubmed">32082969</ArticleId></ArticleIdList></Reference><Reference><Citation>Burslem GM, Crews CM. Small-molecule modulation of protein homeostasis. Chem Rev. 2017;117:11269&#x2013;11301. doi: 10.1021/acs.chemrev.7b00077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.chemrev.7b00077</ArticleId><ArticleId IdType="pubmed">28777566</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinebach C, et al. Homo-PROTACs for the chemical knockdown of cereblon. ACS Chem Biol. 2018;13:2771&#x2013;2782. doi: 10.1021/acschembio.8b00693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschembio.8b00693</ArticleId><ArticleId IdType="pubmed">30118587</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan KH, Zengerle M, Testa A, Ciulli A. Impact of target warhead and linkage vector on inducing protein degradation: comparison of bromodomain and extra-terminal (BET) degraders derived from triazolodiazepine (JQ1) and tetrahydroquinoline (I-BET726) BET inhibitor scaffolds. J Med Chem. 2018;61:504&#x2013;513. doi: 10.1021/acs.jmedchem.6b01912.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.6b01912</ArticleId><ArticleId IdType="pmc">PMC5788402</ArticleId><ArticleId IdType="pubmed">28595007</ArticleId></ArticleIdList></Reference><Reference><Citation>Cyrus K, et al. Impact of linker length on the activity of PROTACs. Mol Biosyst. 2011;7:359&#x2013;364. doi: 10.1039/C0MB00074D.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C0MB00074D</ArticleId><ArticleId IdType="pmc">PMC3835402</ArticleId><ArticleId IdType="pubmed">20922213</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneekloth AR, Pucheault M, Tae HS, Crews CM. Targeted intracellular protein degradation induced by a small molecule: en route to chemical proteomics. Bioorg Med Chem Lett. 2008;18:5904&#x2013;5908. doi: 10.1016/j.bmcl.2008.07.114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2008.07.114</ArticleId><ArticleId IdType="pmc">PMC3175619</ArticleId><ArticleId IdType="pubmed">18752944</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J, et al. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem Biol. 2015;22:755&#x2013;763. doi: 10.1016/j.chembiol.2015.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chembiol.2015.05.009</ArticleId><ArticleId IdType="pmc">PMC4475452</ArticleId><ArticleId IdType="pubmed">26051217</ArticleId></ArticleIdList></Reference><Reference><Citation>Winter GE, et al. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science. 2015;348:1376&#x2013;1381. doi: 10.1126/science.aab1433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aab1433</ArticleId><ArticleId IdType="pmc">PMC4937790</ArticleId><ArticleId IdType="pubmed">25999370</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou B, et al. Discovery of a small-molecule degrader of bromodomain and extra-terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression. J Med Chem. 2018;61:462&#x2013;481. doi: 10.1021/acs.jmedchem.6b01816.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.6b01816</ArticleId><ArticleId IdType="pmc">PMC5788414</ArticleId><ArticleId IdType="pubmed">28339196</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu TT, et al. Specific knockdown of endogenous tau protein by peptide-directed ubiquitin-proteasome degradation. Cell Chem Biol. 2016;23:453&#x2013;461. doi: 10.1016/j.chembiol.2016.02.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chembiol.2016.02.016</ArticleId><ArticleId IdType="pubmed">27105281</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva MC, et al. Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models. Elife. 2019 doi: 10.7554/eLife.45457.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.45457</ArticleId><ArticleId IdType="pmc">PMC6450673</ArticleId><ArticleId IdType="pubmed">30907729</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonali N, Nencetti S, Orlandini E, Ciccone L. Application of PROTAC strategy to TTR-abeta protein-protein interaction for the development of Alzheimer's disease drugs. Neural Regen Res. 2021;16:1554&#x2013;1555. doi: 10.4103/1673-5374.303017.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.303017</ArticleId><ArticleId IdType="pmc">PMC8323684</ArticleId><ArticleId IdType="pubmed">33433479</ArticleId></ArticleIdList></Reference><Reference><Citation>Kargbo RB. PROTAC compounds targeting alpha-synuclein protein for treating neurogenerative disorders: alzheimer's and parkinson's diseases. ACS Med Chem Lett. 2020;11:1086&#x2013;1087. doi: 10.1021/acsmedchemlett.0c00192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsmedchemlett.0c00192</ArticleId><ArticleId IdType="pmc">PMC7294559</ArticleId><ArticleId IdType="pubmed">32550983</ArticleId></ArticleIdList></Reference><Reference><Citation>Montalbano M, et al. TDP-43 and tau oligomers in alzheimer's disease, amyotrophic lateral sclerosis, and frontotemporal dementia. Neurobiol Dis. 2020;146:105130. doi: 10.1016/j.nbd.2020.105130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.105130</ArticleId><ArticleId IdType="pmc">PMC7703712</ArticleId><ArticleId IdType="pubmed">33065281</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X, et al. A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed? Transl Neurodegener. 2021;10:29. doi: 10.1186/s40035-021-00250-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-021-00250-5</ArticleId><ArticleId IdType="pmc">PMC8353789</ArticleId><ArticleId IdType="pubmed">34372914</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo M, et al. The role of TDP-43 propagation in neurodegenerative diseases: integrating insights from clinical and experimental studies. Exp Mol Med. 2020;52:1652&#x2013;1662. doi: 10.1038/s12276-020-00513-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-020-00513-7</ArticleId><ArticleId IdType="pmc">PMC8080625</ArticleId><ArticleId IdType="pubmed">33051572</ArticleId></ArticleIdList></Reference><Reference><Citation>Warraich ST, Yang S, Nicholson GA, Blair IP. TDP-43: a DNA and RNA binding protein with roles in neurodegenerative diseases. Int J Biochem Cell Biol. 2010;42:1606&#x2013;1609. doi: 10.1016/j.biocel.2010.06.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biocel.2010.06.016</ArticleId><ArticleId IdType="pubmed">20601083</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen AK, et al. Induction of amyloid fibrils by the C-terminal fragments of TDP-43 in amyotrophic lateral sclerosis. J Am Chem Soc. 2010;132:1186&#x2013;1187. doi: 10.1021/ja9066207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja9066207</ArticleId><ArticleId IdType="pubmed">20055380</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa Y, Kaneko K, Watanabe S, Yamanaka K, Nukina N. A seeding reaction recapitulates intracellular formation of sarkosyl-insoluble transactivation response element (TAR) DNA-binding protein-43 inclusions. J Biol Chem. 2011;286:18664&#x2013;18672. doi: 10.1074/jbc.M111.231209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.231209</ArticleId><ArticleId IdType="pmc">PMC3099683</ArticleId><ArticleId IdType="pubmed">21454603</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu GC, et al. Delineating the membrane-disrupting and seeding properties of the TDP-43 amyloidogenic core. Chem Commun (Camb) 2013;49:11212&#x2013;11214. doi: 10.1039/c3cc46762g.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/c3cc46762g</ArticleId><ArticleId IdType="pubmed">24154814</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun CS, et al. The influence of pathological mutations and proline substitutions in TDP-43 glycine-rich peptides on its amyloid properties and cellular toxicity. PLoS ONE. 2014;9:e103644. doi: 10.1371/journal.pone.0103644.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0103644</ArticleId><ArticleId IdType="pmc">PMC4121164</ArticleId><ArticleId IdType="pubmed">25090004</ArticleId></ArticleIdList></Reference><Reference><Citation>He RY, et al. Photocontrollable probe spatiotemporally induces neurotoxic fibrillar aggregates and impairs nucleocytoplasmic trafficking. ACS Nano. 2017;11:6795&#x2013;6807. doi: 10.1021/acsnano.7b01645.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.7b01645</ArticleId><ArticleId IdType="pubmed">28653830</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad A, Sivalingam V, Bharathi V, Girdhar A, Patel BK. The amyloidogenicity of a C-terminal region of TDP-43 implicated in amyotrophic lateral sclerosis can be affected by anions, acetylation and homodimerization. Biochimie. 2018;150:76&#x2013;87. doi: 10.1016/j.biochi.2018.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biochi.2018.05.003</ArticleId><ArticleId IdType="pubmed">29751083</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CC, He RY, Huang JJ. Learning from the TDP-43 amyloidogenic sequences in neurodegenerative diseases. Amyloid. 2019;26:154&#x2013;155. doi: 10.1080/13506129.2019.1582513.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13506129.2019.1582513</ArticleId><ArticleId IdType="pubmed">31343307</ArticleId></ArticleIdList></Reference><Reference><Citation>Asakawa K, Handa H, Kawakami K. Optogenetic modulation of TDP-43 oligomerization accelerates ALS-related pathologies in the spinal motor neurons. Nat Commun. 2020;11:1004. doi: 10.1038/s41467-020-14815-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-14815-x</ArticleId><ArticleId IdType="pmc">PMC7035286</ArticleId><ArticleId IdType="pubmed">32081878</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang YS, et al. Full-length TDP-43 forms toxic amyloid oligomers that are present in frontotemporal lobar dementia-TDP patients. Nat Commun. 2014;5:4824. doi: 10.1038/ncomms5824.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms5824</ArticleId><ArticleId IdType="pubmed">25215604</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin L, Vastl J, Gao J. Highly sensitive amyloid detection enabled by thioflavin T dimers. Mol Biosyst. 2010;6:1791&#x2013;1795. doi: 10.1039/c005255h.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/c005255h</ArticleId><ArticleId IdType="pubmed">20614050</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioka S, et al. Synthesis of firefly luciferin analogues and evaluation of the luminescent properties. Chemistry. 2016;22:9330&#x2013;9337. doi: 10.1002/chem.201600278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/chem.201600278</ArticleId><ArticleId IdType="pubmed">27220106</ArticleId></ArticleIdList></Reference><Reference><Citation>Auld DS, et al. A basis for reduced chemical library inhibition of firefly luciferase obtained from directed evolution. J Med Chem. 2009;52:1450&#x2013;1458. doi: 10.1021/jm8014525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm8014525</ArticleId><ArticleId IdType="pmc">PMC3430137</ArticleId><ArticleId IdType="pubmed">19215089</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu X, et al. Flavin as a photo-active acceptor for efficient energy and charge transfer in a model donor&#x2013;acceptor system. Phys Chem Chem Phys. 2012;14:6749&#x2013;6754. doi: 10.1039/c2cp40073a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/c2cp40073a</ArticleId><ArticleId IdType="pubmed">22509495</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishoey M, et al. Translation termination factor GSPT1 is a phenotypically relevant off-target of heterobifunctional phthalimide degraders. ACS Chem Biol. 2018;13:553&#x2013;560. doi: 10.1021/acschembio.7b00969.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschembio.7b00969</ArticleId><ArticleId IdType="pubmed">29356495</ArticleId></ArticleIdList></Reference><Reference><Citation>He RY, et al. Nanoscopic insights of amphiphilic peptide against the oligomer assembly process to treat Huntington's disease. Adv Sci (Weinh) 2020;7:1901165. doi: 10.1002/advs.201901165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.201901165</ArticleId><ArticleId IdType="pmc">PMC6974936</ArticleId><ArticleId IdType="pubmed">31993280</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu ZQ, Mahmood T, Yang PC. Western blot: technique, theory and trouble shooting. N Am J Med Sci. 2014;6:160. doi: 10.4103/1947-2714.128482.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1947-2714.128482</ArticleId><ArticleId IdType="pmc">PMC3978942</ArticleId><ArticleId IdType="pubmed">24741558</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T, Mullane PC, Periz G, Wang J. TDP-43 neurotoxicity and protein aggregation modulated by heat shock factor and insulin/IGF-1 signaling. Hum Mol Genet. 2011;20:1952&#x2013;1965. doi: 10.1093/hmg/ddr076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddr076</ArticleId><ArticleId IdType="pmc">PMC3080607</ArticleId><ArticleId IdType="pubmed">21355045</ArticleId></ArticleIdList></Reference><Reference><Citation>Nussbaum-Krammer CI, Neto MF, Brielmann RM, Pedersen JS, Morimoto RI. Investigating the spreading and toxicity of prion-like proteins using the metazoan model organism C. elegans. J Vis Exp. 2015 doi: 10.3791/52321.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/52321</ArticleId><ArticleId IdType="pmc">PMC4354510</ArticleId><ArticleId IdType="pubmed">25591151</ArticleId></ArticleIdList></Reference><Reference><Citation>Saini A, Chauhan VS. Delineation of the core aggregation sequences of TDP-43 C-terminal fragment. ChemBioChem. 2011;12:2495&#x2013;2501. doi: 10.1002/cbic.201100427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbic.201100427</ArticleId><ArticleId IdType="pubmed">21905193</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang LL, et al. Structural transformation of the amyloidogenic core region of TDP-43 protein initiates its aggregation and cytoplasmic inclusion. J Biol Chem. 2013;288:19614&#x2013;19624. doi: 10.1074/jbc.M113.463828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.463828</ArticleId><ArticleId IdType="pmc">PMC3707662</ArticleId><ArticleId IdType="pubmed">23689371</ArticleId></ArticleIdList></Reference><Reference><Citation>Mompean M, et al. Structural characterization of the minimal segment of TDP-43 competent for aggregation. Arch Biochem Biophys. 2014;545:53&#x2013;62. doi: 10.1016/j.abb.2014.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.abb.2014.01.007</ArticleId><ArticleId IdType="pubmed">24440310</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu L, et al. An ALS-mutant TDP-43 neurotoxic peptide adopts an anti-parallel beta-structure and induces TDP-43 redistribution. Hum Mol Genet. 2014;23:6863&#x2013;6877. doi: 10.1093/hmg/ddu409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu409</ArticleId><ArticleId IdType="pmc">PMC4245047</ArticleId><ArticleId IdType="pubmed">25113748</ArticleId></ArticleIdList></Reference><Reference><Citation>Zacco E, Martin SR, Thorogate R, Pastore A. The RNA-recognition motifs of TAR DNA-binding protein 43 may play a role in the aberrant self-assembly of the protein. Front Mol Neurosci. 2018;11:372. doi: 10.3389/fnmol.2018.00372.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2018.00372</ArticleId><ArticleId IdType="pmc">PMC6190850</ArticleId><ArticleId IdType="pubmed">30356856</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis CA, Wang Y, Klunk WE. imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain. Curr Pharm Des. 2004;10:1469&#x2013;1492. doi: 10.2174/1381612043384772.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1381612043384772</ArticleId><ArticleId IdType="pubmed">15134570</ArticleId></ArticleIdList></Reference><Reference><Citation>Krebs MR, Bromley EH, Donald AM. The binding of thioflavin-T to amyloid fibrils: localisation and implications. J Struct Biol. 2005;149:30&#x2013;37. doi: 10.1016/j.jsb.2004.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsb.2004.08.002</ArticleId><ArticleId IdType="pubmed">15629655</ArticleId></ArticleIdList></Reference><Reference><Citation>Biancalana M, Koide S. Molecular mechanism of thioflavin-T binding to amyloid fibrils. Biochim Biophys Acta. 2010;1804:1405&#x2013;1412. doi: 10.1016/j.bbapap.2010.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbapap.2010.04.001</ArticleId><ArticleId IdType="pmc">PMC2880406</ArticleId><ArticleId IdType="pubmed">20399286</ArticleId></ArticleIdList></Reference><Reference><Citation>GadeMalmos K, et al. ThT 101: a primer on the use of thioflavin T to investigate amyloid formation. Amyloid. 2017;24:1&#x2013;16. doi: 10.1080/13506129.2017.1304905.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13506129.2017.1304905</ArticleId><ArticleId IdType="pubmed">28393556</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, et al. PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies. Cell Res. 2018;28:779&#x2013;781. doi: 10.1038/s41422-018-0055-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-018-0055-1</ArticleId><ArticleId IdType="pmc">PMC6028582</ArticleId><ArticleId IdType="pubmed">29875397</ArticleId></ArticleIdList></Reference><Reference><Citation>Troup RI, Fallan C, Baud MG. Current strategies for the design of PROTAC linkers: a critical review. Explor Target Antitumor Ther. 2020;1:273&#x2013;312. doi: 10.37349/etat.2020.00018.</Citation><ArticleIdList><ArticleId IdType="doi">10.37349/etat.2020.00018</ArticleId><ArticleId IdType="pmc">PMC9400730</ArticleId><ArticleId IdType="pubmed">36046485</ArticleId></ArticleIdList></Reference><Reference><Citation>Han JH, et al. ALS/FTLD-linked TDP-43 regulates neurite morphology and cell survival in differentiated neurons. Exp Cell Res. 2013;319:1998&#x2013;2005. doi: 10.1016/j.yexcr.2013.05.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2013.05.025</ArticleId><ArticleId IdType="pubmed">23742895</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato T, Ito T, Handa H. Cereblon-based small-molecule compounds to control neural stem cell proliferation in regenerative medicine. Front Cell Dev Biol. 2021;9:629326. doi: 10.3389/fcell.2021.629326.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.629326</ArticleId><ArticleId IdType="pmc">PMC7990905</ArticleId><ArticleId IdType="pubmed">33777938</ArticleId></ArticleIdList></Reference><Reference><Citation>Suk TR, Rousseaux MWC. The role of TDP-43 mislocalization in amyotrophic lateral sclerosis. Mol Neurodegener. 2020;15:45. doi: 10.1186/s13024-020-00397-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00397-1</ArticleId><ArticleId IdType="pmc">PMC7429473</ArticleId><ArticleId IdType="pubmed">32799899</ArticleId></ArticleIdList></Reference><Reference><Citation>Lye YS, Chen YR. TAR DNA-binding protein 43 oligomers in physiology and pathology. IUBMB Life. 2022 doi: 10.1002/iub.2603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iub.2603</ArticleId><ArticleId IdType="pubmed">35229461</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaminski Schierle GS, et al. A FRET sensor for non-invasive imaging of amyloid formation in vivo. ChemPhysChem. 2011;12:673&#x2013;680. doi: 10.1002/cphc.201000996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cphc.201000996</ArticleId><ArticleId IdType="pmc">PMC5402868</ArticleId><ArticleId IdType="pubmed">21308945</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhen M, Samuel ADC. C. elegans locomotion: small circuits, complex functions. Curr Opin Neurobiol. 2015;33:117&#x2013;126. doi: 10.1016/j.conb.2015.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2015.03.009</ArticleId><ArticleId IdType="pubmed">25845627</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T, Hwang HY, Hao H, Talbot C, Jr, Wang J. Caenorhabditis elegans RNA-processing protein TDP-1 regulates protein homeostasis and life span. J Biol Chem. 2012;287:8371&#x2013;8382. doi: 10.1074/jbc.M111.311977.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.311977</ArticleId><ArticleId IdType="pmc">PMC3318719</ArticleId><ArticleId IdType="pubmed">22232551</ArticleId></ArticleIdList></Reference><Reference><Citation>Zorba A, et al. Delineating the role of cooperativity in the design of potent PROTACs for BTK. Proc Natl Acad Sci U S A. 2018;115:E7285&#x2013;E7292. doi: 10.1073/pnas.1803662115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1803662115</ArticleId><ArticleId IdType="pmc">PMC6077745</ArticleId><ArticleId IdType="pubmed">30012605</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B, et al. Development of selective small molecule MDM2 degraders based on nutlin. Eur J Med Chem. 2019;176:476&#x2013;491. doi: 10.1016/j.ejmech.2019.05.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2019.05.046</ArticleId><ArticleId IdType="pubmed">31128449</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, et al. Discovery of MD-224 as a first-in-class, highly potent, and efficacious proteolysis targeting chimera murine double minute 2 degrader capable of achieving complete and durable tumor regression. J Med Chem. 2019;62:448&#x2013;466. doi: 10.1021/acs.jmedchem.8b00909.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.8b00909</ArticleId><ArticleId IdType="pmc">PMC6545112</ArticleId><ArticleId IdType="pubmed">30525597</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J, Liu J, Wei W. Degrading proteins in animals: "PROTAC"tion goes in vivo. Cell Res. 2019;29:179&#x2013;180. doi: 10.1038/s41422-019-0144-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-019-0144-9</ArticleId><ArticleId IdType="pmc">PMC6460438</ArticleId><ArticleId IdType="pubmed">30770868</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X, Wei W, Sun Y. PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective. Acta Mater Med. 2022;1:244&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9211018</ArticleId><ArticleId IdType="pubmed">35734447</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Zhang Y, Wu Y, Xing D. Developments of CRBN-based PROTACs as potential therapeutic agents. Eur J Med Chem. 2021;225:113749. doi: 10.1016/j.ejmech.2021.113749.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2021.113749</ArticleId><ArticleId IdType="pubmed">34411892</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46:3&#x2013;26. doi: 10.1016/S0169-409X(00)00129-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0169-409X(00)00129-0</ArticleId><ArticleId IdType="pubmed">11259830</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, et al. Discovery of XL01126: a potent, fast, cooperative, selective, orally bioavailable, and blood-brain barrier penetrant PROTAC degrader of leucine-rich repeat kinase 2. J Am Chem Soc. 2022;144:16930&#x2013;16952. doi: 10.1021/jacs.2c05499.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jacs.2c05499</ArticleId><ArticleId IdType="pmc">PMC9501899</ArticleId><ArticleId IdType="pubmed">36007011</ArticleId></ArticleIdList></Reference><Reference><Citation>Pajouhesh H, Lenz GR. Medicinal chemical properties of successful central nervous system drugs. NeuroRx. 2005;2:541&#x2013;553. doi: 10.1602/neurorx.2.4.541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1602/neurorx.2.4.541</ArticleId><ArticleId IdType="pmc">PMC1201314</ArticleId><ArticleId IdType="pubmed">16489364</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMars KM, Yang C, Candelario-Jalil E. Neuroprotective effects of targeting BET proteins for degradation with dBET1 in aged mice subjected to ischemic stroke. Neurochem Int. 2019;127:94&#x2013;102. doi: 10.1016/j.neuint.2019.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2019.03.004</ArticleId><ArticleId IdType="pubmed">30872008</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, et al. A novel small-molecule PROTAC selectively promotes tau clearance to improve cognitive functions in Alzheimer-like models. Theranostics. 2021;11:5279&#x2013;5295. doi: 10.7150/thno.55680.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.55680</ArticleId><ArticleId IdType="pmc">PMC8039949</ArticleId><ArticleId IdType="pubmed">33859747</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79:416&#x2013;438. doi: 10.1016/j.neuron.2013.07.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.07.033</ArticleId><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E, Gray E, Ansorge O, Talbot K, Turner MR. Towards a TDP-43-based biomarker for ALS and FTLD. Mol Neurobiol. 2018;55:7789&#x2013;7801. doi: 10.1007/s12035-018-0947-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-0947-6</ArticleId><ArticleId IdType="pmc">PMC6132775</ArticleId><ArticleId IdType="pubmed">29460270</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamcik J, Mezzenga R. Amyloid polymorphism in the protein folding and aggregation energy landscape. Angew Chem Int Ed Engl. 2018;57:8370&#x2013;8382. doi: 10.1002/anie.201713416.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.201713416</ArticleId><ArticleId IdType="pubmed">29446868</ArticleId></ArticleIdList></Reference><Reference><Citation>Watkins JA, Alix JJP, Shaw PJ, Mead RJ. Extensive phenotypic characterisation of a human TDP-43(Q331K) transgenic mouse model of amyotrophic lateral sclerosis (ALS) Sci Rep. 2021;11:16659. doi: 10.1038/s41598-021-96122-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-96122-z</ArticleId><ArticleId IdType="pmc">PMC8370970</ArticleId><ArticleId IdType="pubmed">34404845</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SL, et al. A Robust TDP-43 knock-in mouse model of ALS. Acta Neuropathol Commun. 2020;8:3. doi: 10.1186/s40478-020-0881-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-020-0881-5</ArticleId><ArticleId IdType="pmc">PMC6975031</ArticleId><ArticleId IdType="pubmed">31964415</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>